A growing body of evidence suggests that TROP2 is a promising molecular target for the treatment of various malignancies. As novel targeted therapy with great potential, antibody-drug conjugates (ADCs) targeting a specific antigen inherit superiorities of antibody with the drug module, and more remarkably, expand the therapeutic window. For more information about trop 2 adc: https://www.creative-biolabs.com/adc/adc-development-services-targeting-trop2.htm |